• Net sales amounted to TSEK 0 (17).
• Result after taxes amounted to TSEK -11 803 (-7 113).
• Earnings per share before and after dilution amounted to SEK -0,04 (-0,03).
• Cash flow from operating activities after changes in working capital amounted to TSEK -6 784 (-7,178).
• Cash and cash equivalents on the balance sheet date amounted to TSEK 14,711 (13,465).

Company development during the first quarter
First quarter 2025
Turnover and results
Net sales for the first quarter of 2025 amounted to TSEK 0 (17).

Operating costs including capitalized costs and depreciation for the first quarter amounted to TSEK 11 510 (8 087).

Depreciation of capitalized development work and patents has begun as the product development was considered completed in July 2024 and amounts to TSEK 4 827 for the first quarter. The depreciation period is estimated at 5 years.

A smaller portion of the costs has been capitalized during the quarter compared to the corresponding period last year, TSEK 97 (1 741), as the product development is considered to be completed.

The operating profit for the first quarter amounted to TSEK -11 374 (-6 239), and the result after tax amounted to TSEK -11 803 (-7 113).

Cash flow
Cash flow from operating activities during the first quarter amounted to TSEK -6 784 (-7 178).
The total cash flow for the period amounted to TSEK -6 881 (-8 988).

Staff
The average number of employees during the first quarter amounted to 10 (14), of which 4 (4) were women.

Investments, liquidity and financial position
As of March 31, 2025, the accumulated book value of capitalized research and development expenses amounted to TSEK 79 144 (91 144). The amount refers to continued development work related to the company’s products. Depreciation began in the third quarter of 2024. The depreciation period is estimated at 5 years. Accumulated depreciation of capitalized expenses amounts to TSEK 13 967 (0).

Book value of investments in the patent portfolio amounted to TSEK 2 681 (5 156), the majority of which refers to investments in patents and patent applications related to the company’s products. Depreciation began in the third quarter of 2024. Accumulated depreciation of the patents amounts to TSEK 456 (0).

Cash and cash equivalents on the balance sheet date amounted to TSEK 14 711 (13 465).

Equity amounted to TSEK 80 989 (95 978).

The equity ratio was 81 (85) percent.

Significant events during the first quarter of 2025
6 FEBRUARY
Lumito clarifies its product message – increased objectivity in tissue analysis

11 FEBRUARY
Product patent approved for Lumito’s advanced imaging technology in Europe

14 FEBRUARY
Lumito renews its ISO 13485:2016 certification

18 FEBRUARY
Lumito’s Board of Directors and management team increase their shareholdings

27 MARCH
Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery

31 MARCH
Lumito relocates to new premises – improved cost efficiency and strengthened MedTech collaboration

Significant events after the end of the period
7 APRIL
Lumito launches new image visualisation and analysis software in partnership with Katana Labs

11 APRIL
Lumito launches new website - highlighting increasing objectivity in tissue analysis

5 MAY
Lumito featured at AACR 2025

CEO’s comments
Dear shareholders,
The first quarter of 2025 has been marked by our intense efforts to strengthen the company’s financial position and create optimal conditions for future growth and sales. Several actions have been taken, including our relocation to new premises at Ideon Science Park in Lund. With this move, we now share facilities with another MedTech company, enabling synergies and positioning us at the geographic centre of Lund’s Life Science cluster.

We were pleased to announce our collaboration with Concept Life Sciences (CLS), a UK-based CRO. Together, we are evaluating and optimising Scizys, aiming for CLS to soon offer its customers analyses based on Scizys’ labelling and scanning. CLS is also our first CRO partner using our “scan-as-a-service” offering, which allows new users to get started without first investing in their own scanner.

In parallel, the evaluation and optimisation work continues with Truly Labs, with the same objective - enabling Truly Labs to soon offer their clients more efficient drug development using our solution.

As part of refining and strengthening our product message, we have updated our website to more clearly communicate our market position, our offering, and the way we support pharmaceutical companies in developing new, more potent drugs more efficiently.

We have, together with our partner Katana Labs, broadened our offering by launching custom-developed image analysis software. This solution makes it even easier for users to utilise Scizys' unique features.

In addition to ongoing collaborations, we are diligently working to establish new partnerships – both with CROs and with academic research groups as well as larger pharmaceutical and diagnostics companies. The interest in Scizys continues to grow, and our focus on more scientifically grounded marketing is yielding results, including an increased inflow of contacts through our website.

During the quarter, we intensified our sales efforts by actively engaging with to potential customers, building strategic relationships, and advancing ongoing projects. At the same time, we strengthened our market presence by clarifying our offering in customer meetings, marketing materials, and on our website – all to create concrete business opportunities and drive sales.

Thank you for your trust
Once again, I would like to extend my sincere thanks to you, our shareholders. Your continued support is essential and means a lot to us. We are firmly committed to honoring your trust in the best possible way and creating long-term value – both for the company and for you, our investors, who are part of this journey.

Lund, May 2025

Sanna Wallenborg
CEO, Lumito AB